Raltegravir: Difference between revisions
(Created page with "==Administration== *Type: *Dosage Forms: *Routes of Administration: *Common Trade Names: ==Adult Dosing== ==Pediatric Dosing== ==Special Populations== *Drug pregnancy...") |
ClaireLewis (talk | contribs) |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: Antiretroviral, Integrase inhibitor | ||
*Dosage Forms: | *Dosage Forms: 400 mg, 600 mg tablet | ||
*Routes of Administration: | *Routes of Administration: PO | ||
*Common Trade Names: | *Common Trade Names: Isentress | ||
==Adult Dosing== | ==Adult Dosing== | ||
Recommended as part of a regimen including Tenofovir plus Emtricitabine or Lamivudine | |||
*Treatment-naive: 400 mg BID or 1200 mg daily | |||
*Treatment-experienced: 400 mg BID | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
Oral suspension (10 mg/mL): 6 mg/kg/dose BID | |||
*Maximum dose: 100 mg/dose | |||
==Special Populations== | |||
*[[Drug pregnancy categories|Pregnancy Rating]]: C | |||
*Lactation risk: Unknown | |||
===Renal Dosing=== | ===Renal Dosing=== | ||
* | *Mild to Moderate renal disease: No dosage adjustment necessary | ||
* | *ESRD on HD: Dose after dialysis on dialysis days | ||
===Hepatic Dosing=== | ===Hepatic Dosing=== | ||
No dosage adjustment necessary | |||
==Contraindications== | ==Contraindications== | ||
| Line 26: | Line 30: | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*[[Stevens-Johnson Syndrome]] | |||
*Anaphylaxis | |||
*Myopathy/[[Rhabdomyolysis]] | |||
===Common=== | ===Common=== | ||
*Hepatic- increased transaminases | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 9 hours | ||
*Metabolism: | *Metabolism: Hepatic glucuronidation | ||
*Excretion: | *Excretion: Renal | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Reverse transcriptase inhibitor | |||
==Comments== | ==Comments== | ||
| Line 47: | Line 53: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
*https://www.uptodate.com/contents/raltegravir-drug-information?search=Raltegravir&source=search_result&selectedTitle=1~42&usage_type=default&display_rank=1#F5374911 | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] | ||
Latest revision as of 22:15, 23 September 2019
Administration
- Type: Antiretroviral, Integrase inhibitor
- Dosage Forms: 400 mg, 600 mg tablet
- Routes of Administration: PO
- Common Trade Names: Isentress
Adult Dosing
Recommended as part of a regimen including Tenofovir plus Emtricitabine or Lamivudine
- Treatment-naive: 400 mg BID or 1200 mg daily
- Treatment-experienced: 400 mg BID
Pediatric Dosing
Oral suspension (10 mg/mL): 6 mg/kg/dose BID
- Maximum dose: 100 mg/dose
Special Populations
- Pregnancy Rating: C
- Lactation risk: Unknown
Renal Dosing
- Mild to Moderate renal disease: No dosage adjustment necessary
- ESRD on HD: Dose after dialysis on dialysis days
Hepatic Dosing
No dosage adjustment necessary
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Stevens-Johnson Syndrome
- Anaphylaxis
- Myopathy/Rhabdomyolysis
Common
- Hepatic- increased transaminases
Pharmacology
- Half-life: 9 hours
- Metabolism: Hepatic glucuronidation
- Excretion: Renal
Mechanism of Action
- Reverse transcriptase inhibitor